LNTH Lantheus Holdings Inc

Lantheus to Present at the Jefferies London Healthcare Conference

Lantheus to Present at the Jefferies London Healthcare Conference

BEDFORD, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes,, today announced Paul Blanchfield, President, and Bob Marshall, Chief Financial Officer and Treasurer, will present at the Jefferies London Healthcare Conference at 8:00 a.m. GMT (3 a.m. EST) on Wednesday, November 15.

To access a live webcast of the presentation, please visit the Investors section of the Company’s website at . A replay of the webcast will be available on the Company’s website for at least 30 days following the live presentation.

About Lantheus

Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada and Sweden, Lantheus has been providing radiopharmaceutical solutions for more than 65 years. For more information, visit .

Contacts:

Mark Kinarney

Vice President, Investor Relations

978-671-8842

 

Melissa Downs

Senior Director, External Communications

646-975-2533

 



EN
08/11/2023

Underlying

LNTHLantheus Holdings Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Lantheus Holdings Inc

 PRESS RELEASE
Free
LNTH Lantheus Holdin...

Lantheus Announces FDA Approval of PYLARIFY TruVu™ (piflufolastat F 18...

Lantheus Announces FDA Approval of PYLARIFY TruVu™ (piflufolastat F 18) Injection New formulation of its widely-used U.S. market-leading PSMA PET imaging agent combines thediagnostic performance of PYLARIFY® (piflufolastat F 18) with the potential for larger batches and greater patient availability PYLARIFY TruVu™ is expected to launch in 4Q 2026, with a phased geographic rollout to support a seamless customer transition BEDFORD, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to en...

16h / 14m 1 EN
 PRESS RELEASE
Free
LNTH Lantheus Holdin...

Lantheus Receives FDA Tentative Approval for Lutetium Lu 177 Dotatate ...

Lantheus Receives FDA Tentative Approval for Lutetium Lu 177 Dotatate (PNT2003), Radioequivalent to LUTATHERA® BEDFORD, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that it has received U.S. Food and Drug Administration (FDA) tentative approval for the Abbreviated New Drug Application (ANDA) for Lutetium Lu 177 Dotatate (PNT2003), a radioequivalent1 version o...

March 2, 2026 1 EN
 PRESS RELEASE
Free
LNTH Lantheus Holdin...

Lantheus Reports Fourth Quarter and Full Year 2025 Financial Results a...

Lantheus Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update Worldwide revenue of $406.8 million and $1.54 billion for the fourth quarter and full year 2025GAAP fully diluted earnings per share of $0.82 and $3.41 for the fourth quarter and full year 2025Adjusted fully diluted earnings per share of $1.67 and $6.08 for the fourth quarter and full year 2025Repurchased $100 million of shares of common stock in the fourth quarter pursuant to the previously announced stock repurchase plan that was approved by the Board in July 2025Company announced today that ...

February 26, 2026 1 EN
 PRESS RELEASE
Free
LNTH Lantheus Holdin...

Lantheus to Present at March 2026 Investor Conferences

Lantheus to Present at March 2026 Investor Conferences BEDFORD, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company dedicated to helping clinicians Find, Fight, and Follow disease to deliver better patient outcomes, today announced Mary Anne Heino, Executive Chairperson and Chief Executive Officer, will present at the following investor conferences. TD Cowen 46th Annual Health Care ConferenceMarch 3, 2026 at 11:10 a.m. ETLeerink Global Healthcare ConferenceMarch 10, 2026 at 8:00 a.m...

February 24, 2026 1 EN
Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke
EUR 43.03
ZBH ZIMMER BIOMET H...
O5Q OWENS CORNING ... (+28)

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

ZBH ZIMMER BIOMET HOLDINGS INC.
O5Q OWENS CORNING
WHR WHIRLPOOL CORPORATION
CBT CABOT CORPORATION
LNG CHENIERE ENERGY INC.
VC VISTEON CORPORATION
SM SM ENERGY COMPANY
EVEREST RE GROUP LTD.
NWL NEWELL BRANDS INC
LNTH LANTHEUS HOLDINGS INC
KRO KRONOS WORLDWIDE INC.
IOSP INNOSPEC INC.
HY HYSTER-YALE MATERIALS HANDLING INC. CLASS A
GLPI GAMING AND LEISURE PROPERTIES INC.
DECK DECKERS OUTDOOR CORPORATION
CHH CHOICE HOTELS INTERNATIONAL INC.
BCC BOISE CASCADE CO.
APD AIR PRODUCTS AND CHEMICALS INC.
CHE CHEMED CORPORATION
COLM COLUMBIA SPORTSWEAR COMPANY
TNC TENNANT COMPANY
WSO WATSCO INC.
BXC BLUELINX HOLDINGS
FTV FORTIVE CORP.
BCBP BCB BANCORP INC.
BBWI BATH & BODY WORKS INC
AESI NEW ATLAS HOLDCO INC
BGC BGC GROUP INC
02/18/26 February 18, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch